Cheering on a Potential Diabetes Drug from Bench to Bedside (IMAGE)

American Association for the Advancement of Science (AAAS)

Cheering on a Potential Diabetes Drug from Bench to Bedside

Caption

Images showing the movement of the glucose regulator GK (green) in the nucleus in the presence or absence of the new treatment TTP399. This new diabetes treatment activates GK to lower glucose levels.. This material relates to a paper that appeared in the Jan. 16, 2019, issue of Science Translational Medicine, published by AAAS. The paper, by A. Vella at Mayo Clinic in Rochester, Minn.; and colleagues was titled, "Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator."

Credit

A. Vella <i>et al., Science Translational Medicine </i> (2018)

Usage Restrictions

Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact <i>Science</i> for permission.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.